A breakthrough drug called Voxelotor, also known as Oxbryta, produced by Pfizer, is bringing hope for a longer and healthier life for individuals battling sickle cell anaemia.
Voxelotor functions by enhancing the ability of red blood cells to carry oxygen by stabilising haemoglobin, the protein crucial for oxygen transport. Administered in the form of a daily pill, it has the potential to significantly decrease the frequency and severity of pain crises, enhance overall health, and potentially extend lifespan.
Sickle cell disease distorts red blood cells into a sickle shape, resulting in premature death and diminished oxygen distribution throughout the body. It also leads to chronic anaemia, agonising pain episodes (known as crises), and various complications such as stroke, fatigue, delayed growth, and organ damage.
Initially rejected by the United Kingdom’s NHS due to cost concerns, the National Institute for Health and Care Excellence (NICE) has now approved Voxelotor following price negotiations. This approval ensures easier access to this potentially transformative treatment for those in need.
While the drug is currently unavailable in Nigeria, its introduction into the country is anticipated in the near future.
